Condition category
Nutritional, Metabolic, Endocrine
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status
Results overdue

Plain English Summary

Not provided at time of registration

Trial website

Contact information



Primary contact

Miss Rebecca Travers


Contact details

Department for Health
Eastwood 22/23
The Avenue
Claverton Down
United Kingdom
+44 1225 386319

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Effects of lowering blood glucose on T Lymphocyte activation in human adipose tissue


Study hypothesis

Overweight and obesity are major problems and their complications such as cardiovascular disease and type 2 diabetes mellitus (T2DM) pose great burdens on our healthcare systems. There is accumulating evidence to support obesity being a chronic inflammatory disorder mediated in part by expansion of adipose (fat) tissue (AT).

In addition to adipocytes (fat cells), AT contains a range of other cell types including some immune (white blood) cells. Relative proportions of immune cell subpopulations and interactions between different cell types within AT may be important in the development of T2DM.

We want to investigate some of the potential mechanisms leading to adipose tissue dysfunction and how the various cell types in adipose tissue contribute. In particular we are interested in the role of T lymphocytes since these cells are found in adipose tissue, but are normally involved in responses to infections. Our previous research has suggested that there may be important differences in the activation status of certain immune cells located in AT with increased overweight and further relationships with glucose and insulin sensitivity. Since insulin resistance and sensitivity can be rapid to respond to dieting and exercise, we would like to investigate whether immune cells present in subcutaneous adipose tissue may have a role in these early improvements in metabolic health.

Our subjects will include metabolically healthy and unhealthy overweight individuals aged between 45-65 years who fit our criteria for inclusion. After taking some preliminary measurements and monitoring of normal daily activities, subjects will modify normal diet and activity for 10 days to reduce postprandial glucose and will attend 1 session of Laboratory testing before and 1 after this period which will take place in the Physiology Laboratories at the University of Bath.

In this study we hope to learn more about the development of diseases associated with being overweight/obese.

Ethics approval


Study design

Non-randomised interventional and observational; Design type: Prevention, Cohort study

Primary study design


Secondary study design

Non randomised controlled trial

Trial setting

GP practices

Trial type


Patient information sheet


Topic: Primary Care Research Network for England; Subtopic: Not Assigned; Disease: All Diseases


Diet and activity modification, For 10 days, participants will be instructed to consume a glucose lowering diet. This will involve modifications to their normal diet such as replacing high GI foods with lower GI foods.
Participants will also be asked to incorporate some regular activity breaks throughout the 10 days. This involves participants going for a light 2 minute walk every 30 minutes to reduce sedentary time over a period of 8h per day for a total of 30 minutes extra activity per day.

Study Entry : Registration only

Intervention type



Not Applicable

Drug names

Primary outcome measure

T cell number and activation in adipose tissue; Timepoint(s): Pre and post intervention

Secondary outcome measures

1. Adipose tissue cytokine secretion; Timepoint(s): Pre and post intervention
2. Adipose tissue gene expression; Timepoint(s): Pre and post intervention
3. Macrophage number and activation in adipose tissue; Timepoint(s): Pre and post intervention
4. T Lymphocyte and monocyte numbers and activation in blood; Timepoint(s): Pre and post intervention

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Male or postmenopausal* female
2. Aged between 45 to 65years
3. Waist circumference >94cm (males) or >80cm (females)
4. Weight stable for more than 3 months (no change in weight +/- 3%)

Group 1 participants will be overweight with 'normal glucose tolerance' as defined by 2h oral glucose tolerance test (blood glucose <7.8 mmol/L at 2h post 75g glucose drink)
Group 2 participants will be overweight with 'impaired glucose tolerance' (blood glucose >7.8 mmol/L but <11.1mmol/L at 2h post 75g glucose drink)

*postmenopausal defined as no menstruation for at least 1 year (Witteman, Grobbee et al. 1989).; Target Gender: Male & Female; Upper Age Limit 65 years ; Lower Age Limit 45 years

Participant type


Age group




Target number of participants

Planned Sample Size: 22; UK Sample Size: 22; Description: 11 overweight/obese with normal glucose tolerance11 overweight/obese with impaired glucose tolerance

Participant exclusion criteria

1. Personal history of/existing diabetes, cardiovascular disease, metabolic disease or dyslipidaemia
2. Taking medications that may influence lipid or carbohydrate metabolism or immune system function
3. Perform >150minutes/week moderate intensity exercise

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Department for Health
United Kingdom

Sponsor information


University of Bath (UK)

Sponsor details

The Avenue
Claverton Down
United Kingdom

Sponsor type




Funder type


Funder name

BBSRC Industrial CASE Partnership Studentship with Unilever (UK)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

No publications found in PubMed, verifying study status with principal investigator.